Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Webster-Clark

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of the American Geriatrics Society|September 5, 2020
Validation of a 5-Year Mortality Prediction Model among U.S. Medicare BeneficiariesRachael K Ross, Tzy-Mey Kuo, Michael Webster-Clark, et al.
Pharmacoepidemiology and Drug Safety|August 23, 2022
A systematic review of whether COVID-19 randomized controlled trials reported on demographic and clinical characteristicsJoyce Pak, Jennifer L Lund, Alexander Keil, et al.
American Journal of Epidemiology|October 13, 2018
Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target PopulationJin-Liern Hong, Michael Webster-Clark, Michele Jonsson Funk, et al.
American Journal of Epidemiology|February 22, 2021
Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation StudyTil Stürmer, Michael Webster-Clark, Jennifer L Lund, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2022
The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology ExampleEmilie D Duchesneau, Bradford E Jackson, Michael Webster-Clark, et al.
American Journal of Epidemiology|October 12, 2017
Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target PopulationJin-Liern Hong, Michele Jonsson Funk, Robert LoCasale, et al.
JAMA Oncology|October 13, 2022
Comparing Trial and Real-world Adjuvant Oxaliplatin Delivery in Patients With Stage III Colon Cancer Using a Longitudinal Cumulative DoseMichael Webster-Clark, Alexander P Keil, Nicholas Robert, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2025
Core Concepts in Pharmacoepidemiology: Multi-Database Distributed Data NetworksRachelle Haber, Michael Webster-Clark, Nicole Pratt, et al.
Vaccine|February 2, 2022
B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disordersMégane Tanguay, Marianne Boutin, Annemarie Laumaea, et al.
Medical Care|January 20, 2026
Differences in the Measurement of Comorbidities Based on ICD-10-CM Coding Definitions Using Medicare Advantage Encounter Data and Fee-For-Service ClaimsEmilie D Duchesneau, Allison Musty, Elyse Miller, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of the American Geriatrics Society|September 5, 2020
Validation of a 5-Year Mortality Prediction Model among U.S. Medicare BeneficiariesRachael K Ross, Tzy-Mey Kuo, Michael Webster-Clark, et al.
Pharmacoepidemiology and Drug Safety|August 23, 2022
A systematic review of whether COVID-19 randomized controlled trials reported on demographic and clinical characteristicsJoyce Pak, Jennifer L Lund, Alexander Keil, et al.
American Journal of Epidemiology|October 13, 2018
Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target PopulationJin-Liern Hong, Michael Webster-Clark, Michele Jonsson Funk, et al.
American Journal of Epidemiology|February 22, 2021
Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation StudyTil Stürmer, Michael Webster-Clark, Jennifer L Lund, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2022
The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology ExampleEmilie D Duchesneau, Bradford E Jackson, Michael Webster-Clark, et al.
American Journal of Epidemiology|October 12, 2017
Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target PopulationJin-Liern Hong, Michele Jonsson Funk, Robert LoCasale, et al.
JAMA Oncology|October 13, 2022
Comparing Trial and Real-world Adjuvant Oxaliplatin Delivery in Patients With Stage III Colon Cancer Using a Longitudinal Cumulative DoseMichael Webster-Clark, Alexander P Keil, Nicholas Robert, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2025
Core Concepts in Pharmacoepidemiology: Multi-Database Distributed Data NetworksRachelle Haber, Michael Webster-Clark, Nicole Pratt, et al.
Vaccine|February 2, 2022
B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disordersMégane Tanguay, Marianne Boutin, Annemarie Laumaea, et al.
Medical Care|January 20, 2026
Differences in the Measurement of Comorbidities Based on ICD-10-CM Coding Definitions Using Medicare Advantage Encounter Data and Fee-For-Service ClaimsEmilie D Duchesneau, Allison Musty, Elyse Miller, et al.
Pageof 5